Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentNorhakim Yahya, Scott J Pollack, Richard Margolin, et al.Plos One|October 13, 2015
Investigating Apoptozole as a Chemical Probe for HSP70 InhibitionLindsay E Evans, Matthew D Cheeseman, Norhakim Yahya, et al.Current Opinion in Investigational Drugs (London, England : 2000)|January 29, 2005
Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous proteaseScott J Pollack, Huw LewisCleveland Clinic Journal of Medicine|November 4, 2005
Depression in older patients with neurologic illness: causes, recognition, managementAlan Carson, Richard MargolinCurrent Drug Targets. CNS and Neurological Disorders|May 29, 2003
Small molecule Trk receptor agonists and other neurotrophic factor mimeticsScott J Pollack, Sarah J HarperDrug News & Perspectives|April 5, 2003
Trk Neurotrophin Receptor ActivatorsScott J. Pollack, Sarah J. HarperPlos One|April 16, 2011
Recombinant complement receptor 2 radiolabeled with [99mTc(CO)3]+: a potential new radiopharmaceutical for imaging activated complementAdam Badar, Sarah DeFreitas, James M McDonnell, et al.Molecular Immunology|August 13, 2013
Conformational plasticity at the IgE-binding site of the B-cell receptor CD23Balvinder Dhaliwal, Marie O Y Pang, Daopeng Yuan, et al.Journal of Molecular Neuroscience : MN|September 6, 2002
Development of indole-3-propionic acid (OXIGON) for Alzheimer's diseasePaul E Bendheim, Burkhard Poeggeler, Eyal Neria, et al.Archives of Biochemistry and Biophysics|May 24, 2005
Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitorsMichael Fricker, Philip Lograsso, Semantha Ellis, et al.Pageof 3